| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 02/16/2006 | US20060035377 Pathogen-resistant grape plants |
| 02/16/2006 | US20060035362 Novel human hydrolase family members and uses thereof |
| 02/16/2006 | US20060035358 Nucleotide sequence encoding a protein that regulates an enzyme involved in the production of reactive oxygen intermediates that affect cell division; determining the activity of drugs that affect the biological activity of these proteins |
| 02/16/2006 | US20060035347 Polynucleotides encoding polypeptides involved in amino acid biosynthesis in Methylophilus methylotrophus |
| 02/16/2006 | US20060035340 Fermenting an appropriate microorganism using glucose as a carbon source and operating two chromatographic separation steps wherein ion exchange chromatography is followed by hydrophobic interaction chromatography, wherein the diphtheria toxin has a purity of at least 98%. |
| 02/16/2006 | US20060035339 IL-8 like protein |
| 02/16/2006 | US20060035338 Method and apparatus for the production of soluble MHC antigens and uses thereof |
| 02/16/2006 | US20060035337 Leukocyte adhesion inhibitor-1 polypeptide for use in the treatment of cancer, tumors, chronic infections, leukemia, T-cell mediated auto-immune diseases, parasitic infections, psoriasis, asthma, allergy, to regulate hematopoiesis, to stimulate growth factor activity, to inhibit angiogenesis |
| 02/16/2006 | US20060035336 Prokaryotic collagen-like proteins and uses thereof |
| 02/16/2006 | US20060035335 Use of HCV proteins |
| 02/16/2006 | US20060035334 Apo-2 receptor |
| 02/16/2006 | US20060035332 Novel RFRP-3 and DNA thereof |
| 02/16/2006 | US20060035331 G-protein coupled receptors |
| 02/16/2006 | US20060035330 Non aggregating fluorescent proteins and methods for using the same |
| 02/16/2006 | US20060035329 Human hairless gene and protein |
| 02/16/2006 | US20060035328 Artery-and vein-specific proteins and uses therefor |
| 02/16/2006 | US20060035327 with changed spatial configuration and improved efficacy; preventing or treating viral diseases; antitumor agents; also an artificial gene which codes for the interferon |
| 02/16/2006 | US20060035326 Genes |
| 02/16/2006 | US20060035325 Regulated apoptosis |
| 02/16/2006 | US20060035324 BASB019 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses |
| 02/16/2006 | US20060035322 T-cell epitopes in erythropoietin |
| 02/16/2006 | US20060035319 Introducing DNA sequence encoding heterologous antigenic peptide; elicits immunogenic response; vaccine against cervical cancer |
| 02/16/2006 | US20060035318 Teneurin c-terminal associated peptides (tcap) and uses thereof |
| 02/16/2006 | US20060035316 Plasmids expressing human insulin and the preparation method for human insuling thereby |
| 02/16/2006 | US20060035315 Transporters and ion channels |
| 02/16/2006 | US20060035314 Receptors and signalling proteins capable of binding meiotic acting sterols (MAS) |
| 02/16/2006 | US20060035305 Synthetic peptides, conjugation reagents and methods |
| 02/16/2006 | US20060035303 JNK3 modulators and methods of use |
| 02/16/2006 | US20060035297 Reagents and methods for mycophenolic acid immunoassay |
| 02/16/2006 | US20060035294 Use of the protein maba (fabg1) of mycobacterium tuberculosis for designing and screening antibiotics |
| 02/16/2006 | US20060035293 Antibodies, polypeptides and polynucleotides, used for detection, prevention and treatment of diseases caused by gramnegative bacteria |
| 02/16/2006 | US20060035289 Affinity fluorescent proteins and uses thereof |
| 02/16/2006 | US20060035286 Monitor protein for measuring processing of protein |
| 02/16/2006 | US20060035285 Method for identifying modulators of human orexin-2 receptor |
| 02/16/2006 | US20060035284 Methods for isolating molecular mimetics of unique Neisseria meningitidis serogroup B epitopes |
| 02/16/2006 | US20060035283 Prophylaxis and therapy of diseases or disorders related to glutamate excitotoxicity, caused by cerebral infarcts, head trauma, seizures, and anoxia; disorders related to NMDA receptor glutamate excitotoxicity, including for example, cerebral ischemia, Parkinson's disease, Huntington's disease |
| 02/16/2006 | US20060035278 Methods and compositions for modulating HGF/Met |
| 02/16/2006 | US20060035263 DRG11-responsive (DRAGON) gene family |
| 02/16/2006 | US20060035260 Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2 and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses |
| 02/16/2006 | US20060035249 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| 02/16/2006 | US20060035232 making in vitro peptide expression libraries and for the isolation of nucleotide sequences encoding peptides of interest; constructing and screening DNA libraries for DNA sequences that encode biologically active molecules |
| 02/16/2006 | US20060035230 Bacterial effector proteins which inhibit programmed cell death |
| 02/16/2006 | US20060035213 POSH nucleic acids, polypeptides and related methods |
| 02/16/2006 | US20060035209 Screening method |
| 02/16/2006 | US20060034932 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060034870 Increasing the immunogenicity of an antigen or a hapten by attaching it to an adjuvant having a fragment with a specific amino acid sequence of the P40 protein of Klebsiella pneumoniae to form an immunogenic complex |
| 02/16/2006 | US20060034866 Adipocyte complement related protein homolog zacrp3 |
| 02/16/2006 | US20060034864 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| 02/16/2006 | US20060034863 Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof |
| 02/16/2006 | US20060034861 HCV E1 comprising specific disulfide bridges |
| 02/16/2006 | US20060034860 Protein-protein interactions in human immunodeficiency virus |
| 02/16/2006 | US20060034859 Naturally processed measles virus peptides eluted from class II HLA molecules |
| 02/16/2006 | US20060034858 A beta or an immunogenic fragment thereof presented by a virus or bacteria as part of an immunogenic composition effective to induce an immunogenic response comprising antibodies against A beta |
| 02/16/2006 | US20060034857 Administering an isolated polynucleotide encoding a Notch ligand comprising a Delta Serrate Ligand (DSL) domain to a cell of a patient; the Notch ligand is expressed and interacts with a Notch receptor to reduce T-cell activation; antiallergens; graft rejection; autoimmune disease |
| 02/16/2006 | US20060034856 Epha2 antigen t epitopes |
| 02/16/2006 | US20060034855 Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein |
| 02/16/2006 | US20060034854 Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria |
| 02/16/2006 | US20060034853 Novel human virus causing respiratory tract infection and uses thereof |
| 02/16/2006 | US20060034852 Comprising transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor moiety and an immunoglobulin moiety comprising a heavy chain constant region of an immunoglobulin; interfere with binding of a tumor necrosis factor receptor with its ligand; antitumor agents |
| 02/16/2006 | US20060034850 Antibodies as T cell receptor mimics, methods of production and uses thereof |
| 02/16/2006 | US20060034836 administering immunoglobulins linked to proteins having amino acid replacements in the amino acid sequence, to increase the circulating half-life in vivo than a corresponding antibody-based fusion proteins without amino acid replacements; reducing tumor size and metastasis in mammals |
| 02/16/2006 | US20060034826 contacting an immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1); inhibits signaling via PD-1 |
| 02/16/2006 | US20060034813 Expression of proteins in cord blood-derived endothelial cells |
| 02/16/2006 | US20060034804 Adenoviral vectors having a protein IX deletion |
| 02/16/2006 | US20060034799 Tissue protective cytokines for the protection, restoration, and enhancement fo responsive cells, tissues and organs |
| 02/16/2006 | US20060034764 Fusion proteins of mycobacterium tuberculosis antigens and their uses |
| 02/16/2006 | US20060034761 Heat shock protein as a targeting agent for endothelium-specific in vivo transduction |
| 02/16/2006 | US20060034758 Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof |
| 02/16/2006 | DE4229526B4 Vorrichtung zur Aufnahme und zum Einbringen von biologisch aktiven Geweben oder Zellen in den menschlichen Körper Device for receiving and for introducing biologically active tissues or cells in the human body |
| 02/16/2006 | CA2742442A1 Low temperature molding process for making solid biodegradable articles |
| 02/16/2006 | CA2576576A1 Gastrin-specific interfering rna |
| 02/16/2006 | CA2576415A1 Knockout nonhuman animal |
| 02/16/2006 | CA2575994A1 Optimizing expression of active botulinum toxin type a |
| 02/16/2006 | CA2575989A1 Means and methods for producing a stabilized cell of interest |
| 02/16/2006 | CA2575830A1 Rage fusion proteins and methods of use |
| 02/16/2006 | CA2575596A1 Cell surface glycoprotein |
| 02/16/2006 | CA2575406A1 Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
| 02/16/2006 | CA2575293A1 Recombinant live fowlpox virus vectors and their use in pharmaceutical compositions against hepatitis c virus |
| 02/16/2006 | CA2575123A1 Peptide sequence for modulation of delta protein kinase c |
| 02/16/2006 | CA2573283A1 Methods for identifying factors for differentiating definitive endoderm |
| 02/16/2006 | CA2572947A1 Method for purifying a protein of the cystine-knot superfamily |
| 02/16/2006 | CA2571956A1 Methods and systems for predicting protein-ligand coupling specificities |
| 02/16/2006 | CA2570324A1 Rage fusion proteins and methods of use |
| 02/16/2006 | CA2514438A1 Process for the preparation of a von willebrand factor (vwf) concentrate by chromotographic means and vwf prepared thereby |
| 02/15/2006 | EP1626096A2 In vitro method of detecting a cell proliferative disorder involving fibroblast growth factor homologous factor-1 (FHF-1) |
| 02/15/2006 | EP1626084A1 Compositions and methods for the diagnosis of tumours |
| 02/15/2006 | EP1626058A1 Compositions and methods for the diagnosis of tumour |
| 02/15/2006 | EP1626057A1 Chimpanzee trace amine associated receptors |
| 02/15/2006 | EP1626056A2 Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity |
| 02/15/2006 | EP1626054A1 Oligopeptide |
| 02/15/2006 | EP1625857A2 Conjugates of defined stoichiometry |
| 02/15/2006 | EP1625852A1 Chimeric flavivirus vaccines |
| 02/15/2006 | EP1625395A1 Method for identifying tff2 regulating agents and agents identified using said method |
| 02/15/2006 | EP1625378A2 Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
| 02/15/2006 | EP1625222A2 Broadening adenovirus tropism |
| 02/15/2006 | EP1625221A2 Method for the preparation of transgenic plants characterised by geminivirus lasting resistance |
| 02/15/2006 | EP1625214A1 New enterovirus, vaccines, medicaments and diagnostic kits |
| 02/15/2006 | EP1625211A2 Metabolically engineered bacterial strains having non-functional endogenous gluconate transporters |
| 02/15/2006 | EP1625209A2 Immunoglobulin chimeric monomer-dimer hybrids |
| 02/15/2006 | EP1625208A2 Novel lipolytic enzyme lip2 |